ArticleFrontiers in medicine2026
Complication rates and management in sentinel lymph node biopsy for endometrial cancer: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systematic pelvic lymph node dissection (PLND) is the conventional staging procedure for early-stage endometrial cancer but is associated with substantial morbidity, particularly lower-limb lymphedema. Sentinel lymph node biopsy (SLNB) is a less invasive alternative, yet real-world evidence on complications and patient-reported quality of life (QoL) remains limited. Objective: To compare perioperative outcomes, postoperative complications, and QoL between SLNB and PLND in low- to intermediate-risk endometrial cancer, and to determine whether surgical approach is an independent risk factor for complications. Methods: We retrospectively analyzed 150 eligible patients with early-stage endometrial cancer treated at a gynecologic oncology center between January 2020 and December 2023, with ≥12 months of follow-up. Based on contemporaneously documented clinical decision-making and patient preference, patients were assigned to the SLNB group ( Results: Baseline characteristics (age, BMI, FIGO stage) were comparable between groups (all Conclusion: In low- to intermediate-risk early-stage endometrial cancer, SLNB provides effective staging with reduced surgical burden, fewer postoperative complications-particularly lymphedema-and earlier recovery of QoL compared with systematic PLND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.